What’s the current market cap for Neuropace stock?

Neuropace (NPCE) has a market cap of $555M as of May 23, 2026.

What is the P/E ratio for Neuropace stock?

The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of May 23, 2026.

Does Neuropace stock pay dividends?

No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of May 23, 2026.

When is the next Neuropace dividend payment date?

Neuropace (NPCE) stock does not pay dividends to its shareholders.

What is the beta indicator for Neuropace?

Neuropace (NPCE) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Neuropace stock | $NPCE Share Price

About Neuropace

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Ticker

$NPCE

Sector

Health

Primary listing

NASDAQ

Employees

220

Headquarters

Mountain View, United States

Website

www.neuropace.com

Neuropace Metrics

BasicAdvanced

$555m

-

-$0.65

1.93

-

What the Analysts think about Neuropace

Analyst ratings (Buy, Hold, Sell) for Neuropace stock.

Neuropace Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Neuropace Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Neuropace News

AllArticlesVideos

NeuroPace Q1 Earnings Call Highlights

MarketBeat·1 week ago

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

Business Wire·4 weeks ago

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

Business Wire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.